Rosacea is a chronic skin disorder characterized by facial flushing, persistent erythema, telangiectasias, and inflammatory papules and pustules. In addition to the physical manifestations, rosacea may contribute to lower self-esteem, thereby having significant psychosocial implications. Some patients do not respond to conventional treatments for rosacea or are unable to tolerate the adverse effects; therefore, effective new therapies are needed. We sought to investigate the safety and efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, for the treatment of moderate to severe inflammatory rosacea. Apremilast modulates multiple proinflammatory and anti-inflammatory pathways through targeted phosphodiesterase type 4 inhibition, including augmenting interleukin 10 production, which in turn suppresses other proinflammatory cytokines. Inhibitors of phosphodiesterase type 4 have been tested for treatment of many inflammatory dermatologic diseases but never for rosacea.
BJ Thompson, M Furniss, W Zhao, B Chakraborty, J Mackay-Wiggan
An Oral Phosphodiesterase Inhibitor (Apremilast) for Inflammatory Rosacea in Adults: A Pilot Study
JAMA Dermatol 2014 Jul 23;[EPub Ahead of Print]